神经病学与神经康复学杂志2025，Vol.21Issue(4)：251-258,8.DOI:10.12022/jnnr.2025-0151
《英国神经科医师协会2024年多发性硬化疾病修饰治疗指南》解读
Comments on the"using disease-modifying treatments in multiple sclerosis:Association of British Neurologists(ABN)2024 guidance"
万文斌 1谢冲 1姚小英 1张瑛 1王刚1
作者信息
- 1. 上海交通大学医学院附属仁济医院神经内科,上海 200127
- 折叠
摘要
Abstract
The"using disease-modifying treatments in multiple sclerosis:Association of British Neurologists(ABN)2024 guidance"(hereinafter referred to as the 2024 ABN guideline)introduces significant updates to treatment strategies for multiple sclerosis(MS).The guideline emphasizes that MS should be considered a single disease characterized by both relapsing and progressive components,with mechanism of dynamic coexistence of inflammation and neurodegeneration.For the first time,the guideline adopts a comprehensive management approach termed"treatment-monitoring-transition",categorizing disease-modifying treatment(DMT)drugs into four groups including medium/high-efficacy treatments for relapsing-remitting MS and specific medications for progressive MS.The guideline also compares the advantages and disadvantages of advanced treatment versus early high-efficacy treatment,recommending that patients with high disease activity prioritize early high-efficacy interventions.Additionally,special attention is given to medication considerations for pregnant women.This article provides an interpretation of the full-cycle management approach for DMT and decision-making for specific patient populations in clinical practice,in alignment with the 2024 ABN guideline.关键词
多发性硬化/疾病修饰治疗/早期高效/进阶治疗/指南解读Key words
Multiple sclerosis/Disease-modifying treatment/Early high-efficacy/Advanced treatment/Guideline interpretation引用本文复制引用
万文斌,谢冲,姚小英,张瑛,王刚..《英国神经科医师协会2024年多发性硬化疾病修饰治疗指南》解读[J].神经病学与神经康复学杂志,2025,21(4):251-258,8.
